Targeted Genetics, IAVI, CCRI begin human trial of vaccine candidate to prevent HIV/AIDS
IAVI releaseSEATTLE, NEW YORK, 9 December 2003—Targeted Genetics Corp. (NASDAQ:TGEN), the nonprofit International AIDS Vaccine Initiative (IAVI) and Columbus Children’s Research Institute (CCRI) have begun testing in humans a new vaccine candidate to prevent HIV/AIDS. A human clinical trial of vaccine candidate tgAAC09 has begun in Belgium. tgAAC09 is different from most other AIDS vaccine candidates now in trials in that it is potentially a single-shot vaccine, rather than one that would require multiple injections over time. A single-shot AIDS vaccine would be particularly useful for developing countries, where most new HIV infections occur.
—Posted: December 9, 2003
More news headlines: This week | Last week | Search archive